| The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| The landscape of disease: mapping aplastic anemia |
|
Blood |
Aplastic Anemia |
| The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| T cell dysfunctions in myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria |
|
Blood |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Germline DDX41 mutations define a significant entity within adult MDS/AML patients |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria |
|
Blood |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Genetics of Progression From MDS to Secondary Leukemia |
|
Blood |
Myelodysplastic Syndromes (MDS) |
